ATE488584T1 - Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften - Google Patents

Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften

Info

Publication number
ATE488584T1
ATE488584T1 AT00929588T AT00929588T ATE488584T1 AT E488584 T1 ATE488584 T1 AT E488584T1 AT 00929588 T AT00929588 T AT 00929588T AT 00929588 T AT00929588 T AT 00929588T AT E488584 T1 ATE488584 T1 AT E488584T1
Authority
AT
Austria
Prior art keywords
domains
generating
materials
binding properties
customized
Prior art date
Application number
AT00929588T
Other languages
English (en)
Inventor
Kalle Saksela
Marita Hiipakka
Original Assignee
Next Biomed Technologies Nbt Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Next Biomed Technologies Nbt Oy filed Critical Next Biomed Technologies Nbt Oy
Application granted granted Critical
Publication of ATE488584T1 publication Critical patent/ATE488584T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Graft Or Block Polymers (AREA)
  • Ceramic Products (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Photoreceptors In Electrophotography (AREA)
AT00929588T 1999-05-26 2000-05-26 Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften ATE488584T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13608599P 1999-05-26 1999-05-26
PCT/FI2000/000477 WO2000072742A2 (en) 1999-05-26 2000-05-26 Methods and materials for generating sh3 domains with tailored binding properties

Publications (1)

Publication Number Publication Date
ATE488584T1 true ATE488584T1 (de) 2010-12-15

Family

ID=22471216

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00929588T ATE488584T1 (de) 1999-05-26 2000-05-26 Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften

Country Status (9)

Country Link
US (1) US6794144B1 (de)
EP (1) EP1181358B1 (de)
JP (1) JP2003500080A (de)
AT (1) ATE488584T1 (de)
AU (1) AU4761100A (de)
CA (1) CA2374180C (de)
DE (1) DE60045243D1 (de)
ES (1) ES2371464T3 (de)
WO (1) WO2000072742A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10109532C1 (de) * 2001-02-28 2002-06-13 Matthias Geyer Fusionsprotein zum Blocken des HIV Nef-Proteins
US7846746B2 (en) * 2001-04-10 2010-12-07 Children's Medical Center Corporation Methods of analysis and labeling of protein-protein interactions
AU2005319578A1 (en) * 2004-11-24 2006-06-29 Neopro Labs, Llc Methods and compositions for treating conditions
EP2015765A4 (de) * 2006-03-28 2011-11-23 Neopro Labs Llc Verfahren und zusammensetzungen zur behandlung von erkrankungen
EP1930342B1 (de) 2006-12-04 2012-01-25 Institut Pasteur Als Gerüst verwendeter OB-Fold zur Entwicklung neuer spezifischer Bindemittel
WO2008144675A1 (en) * 2007-05-17 2008-11-27 Neopro Labs, Llc Crystalline and amorphous forms of peptide
US20090069237A1 (en) * 2007-07-18 2009-03-12 Hanna Skubatch Methods and compositions for treating conditions
EP3747457A3 (de) 2013-01-17 2021-03-03 Medizinische Hochschule Hannover Faktor-1-protein, faktor-2-protein und inhibitoren davon zur verwendung bei der behandlung und prävention von erkrankungen
WO2016105542A2 (en) 2014-12-24 2016-06-30 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
FI126633B (en) 2015-07-10 2017-03-15 Next Biomed Therapies Oy Method for the preparation of a library of derivatives of the SH3 domain of recombinant nephrocystin (NPHP1)
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CN108883150A (zh) 2015-11-19 2018-11-23 阿斯克雷佩西治疗公司 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
EP3426278B1 (de) 2016-03-07 2024-01-03 Vib Vzw Einzeldomänenantikörper gegen cd20
EP3455245A2 (de) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutisches targeting von nichtzellulären strukturen
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
MX2019003895A (es) 2016-10-04 2019-10-07 Asclepix Therapeutics Inc Compuestos y metodos para activar la señalizacion tie2.
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3661536A4 (de) 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. Verfahren zur identifizierung und herstellung von pharmazeutischen wirkstoffen zur aktivierung eines tie2-rezeptors
WO2019075056A1 (en) 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
EP3743448A4 (de) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. Xcr1-bindende wirkstoffe und verwendungen davon
KR102877915B1 (ko) 2018-02-05 2025-10-29 오리오니스 바이오사이언시즈 인코포레이티드 섬유아세포 결합제 및 이의 용도
US12410225B2 (en) 2018-11-08 2025-09-09 Orionis Biosciences, Inc Modulation of dendritic cell lineages
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
JP2022520632A (ja) 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
EP4384219A4 (de) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. Zusammensetzungen, dosen und verfahren zur behandlung von schilddrüsenaugenkrankheit
WO2023089243A1 (en) * 2021-11-19 2023-05-25 Pandemblock Oy Sh3 domain derivatives targeting receptor binding domain (rbd) of sars-cov-2 spike protein
JP2025523630A (ja) 2022-07-04 2025-07-23 ブイアイビー ブイゼットダブリュ 血液－脳脊髄液関門通過抗体
TW202430574A (zh) 2022-11-30 2024-08-01 美商積分分子股份有限公司 針對密連蛋白６之抗體，包括其雙特異性格式
AU2024243709A1 (en) 2023-04-03 2025-11-06 Katholieke Universiteit Leuven Blood-brain barrier crossing antibodies
AU2024287547A1 (en) 2023-07-07 2026-01-22 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
WO2025093683A1 (en) 2023-11-03 2025-05-08 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
WO2025136985A1 (en) 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2159895A (en) 1994-03-11 1995-09-25 Ariad Pharmaceuticals, Inc. Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
DE69534920T2 (de) * 1994-07-22 2007-04-05 University Of North Carolina Src SH3 BINDENDE PEPTIDE UND VERFAHREN ZU IHRER ISOLIERUNG UND VERWENDUNG
WO1996031625A1 (en) * 1995-04-07 1996-10-10 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same

Also Published As

Publication number Publication date
CA2374180C (en) 2012-09-11
WO2000072742A2 (en) 2000-12-07
CA2374180A1 (en) 2000-12-07
US6794144B1 (en) 2004-09-21
EP1181358A2 (de) 2002-02-27
AU4761100A (en) 2000-12-18
ES2371464T3 (es) 2012-01-03
EP1181358B1 (de) 2010-11-17
WO2000072742A3 (en) 2001-02-22
DE60045243D1 (de) 2010-12-30
JP2003500080A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
ATE488584T1 (de) Verfahren und materialien zur erzeugung von sh3 domänen mit angepassten bindungseigenschaften
DE69839451D1 (de) Prozess zur herstellung und anwendung von anionischen lehm materialien
ZA975851B (en) Hepatocyte grown factor receptor agonists and uses thereof
DE60130797D1 (de) Verwendung von spezifischen erbb4 antagonisten zur behandlung von stenose
AU2002305450A1 (en) Proteomimetic compounds and methods
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
TW200603830A (en) Methods for treating bone cancer pain by administering a nerve growth factor antagonist
GEP20063830B (en) Nogo Receptor-Mediated Blockade of Axonal Growth
DE60334995D1 (de) Verfahren zur herstellung von amorphen und keramischen stoffen mittels schmelzspinnen
ATE406163T1 (de) Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren
ATE322252T1 (de) Verfahren zur herstellung und sammlung von kristallinen partikeln
YU84903A (sh) Antitela koja blokiraju cripto i njihova upotreba
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EP1064308A4 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
PT1157042E (pt) Produção de anticorpos tetravalentes
DE69732535D1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
DE69940206D1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
DE3682891D1 (de) Gewebeplasminogen-aktivator-mutant, dafuer kodierende rekombinante genetische information und verfahren zur herstellung dieser mutanten, deren verwendung und pharmazeutische zusammensetzungen.
ATE495193T1 (de) Bag3-antikörper zur nutzung in forschung, diagnose und der behandlung von krankheiten, an denen zelltod beteiligt ist
ATE501730T1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
ATE347536T1 (de) Chlorsilanblends zur behandlung von quarzfuellstoffen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties